Continuous Peritoneal Dialysis-Associated Peritonitis: A Review and Current Concepts

Seminars in Dialysis

Volumn 16, Issue 6, 2003, Pages 428-437

  Troidle, Laura ^a   Gorban Brennan, Nancy ^a   Kliger, Alan ^a   Finkelstein, Fredric O ^a,b  

^a New Haven CARD   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; NYSTATIN; PIPERACILLIN; PSEUDOMONIC ACID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BIOFILM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DOSE RESPONSE; FOLLOW UP; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; OINTMENT; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONITIS; RECURRENT INFECTION; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; BIOFILMS; DEPRESSION; HUMANS; PERITONEAL DIALYSIS; PERITONITIS; RECURRENCE; RISK FACTORS;

EID: 0346218057     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139X.2003.16095.x     Document Type: Conference Paper

References (108)

1. U.S. Renal Data System: USRDS 2002 Annual Data Report. Bethesda, MD: National Institutes of Health, Department of Health and Human Services, 2002
2. Krishnan M, Thodis E, Ikonomopoulos D, Vidgen E, Chu M, Bargman JM, Vas SI, Oreopoulos DG: Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit Dial Int 22:573-581, 2002
3. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Kawaguchi Y, Piraino B, Riella M, Vas S: Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 20:396-411, 2000
4. Fielding RE, Clemenger M, Goldberg L, Brown EA: Treatment and outcome of peritonitis in automated peritoneal dialysis, using a once-daily cefazolin-based regimen. Perit Dial Int 22:345-349, 2002
5. Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, Harding G: Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36:1009-1013, 2000
6. Thodis E, Bhaskaran S, Pasadakis PP, Bargman JM, Vas SI, Oreopoulos DC: Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit-site. Perit Dial Int 18:261-270, 1998
7. Vas SI: Microbiologic aspects of chronic ambulatory peritoneal dialysis (CAPD). Kidney Int 23:83-92, 1983
8. Troidle L, Gorban-Brennan N, Kliger A, Finkelstein F: Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 32:623-628, 1998
9. Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ: Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 39:1278-1286, 2002
10. Troidle L, Gorban-Brennan N, Finkelstein E, Finkelstein FO: First and second episodes of peritonitis. Perit Dial Int 22(suppl 1):S41, 2002
11. Fried LF, Bernardini J, Johnston JR, Piraino B: Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 7:2176-2182, 1996
12. Kiernan L, Finkelstein FO, Kliger AS, Gorban-Brennan N, Juergensen P, Mooraki A, Brown E: Outcome of polymicrobial peritonitis in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 25:461-464, 1995
13. Holley J, Bernardini J, Piraino B: Polymicrobial peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 19:162-166, 1992
14. Troidle LK, Kliger AS, Goldie SJ, Gorban-Brennan N, Finkelstein FO: CPD-associated peritonitis of nosocomial origin. Perit Dial Int 16:505-510, 1996
15. Troidle LK, Gorban-Brennan N, Kliger AS, Finkelstein FO: Continuous cycler therapy, manual peritoneal dialysis therapy, and peritonitis. Adv Perit Dial 14:137-141, 1998
16. Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E: PD catheter removal for acute peritonitis: factors associated with prolonged post-operative hospitalization. Am J Kidney Dis, (in press)
17. Burkart JM, Hylander B, Durnell-Figel T, Roberts D: Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 10:41-43, 1990
18. Kieman L, Kliger A, Gorban-Brennan N, Juergensen P, Tesin D, Vonesh E, Finkelstein F: Comparison of continuous ambulatory peritoneal dialysis-related infections with different "Y-tubing" exchange systems. J Am Soc Nephrol 5:1835-1838, 1995
19. Diaz-Buxo JA, Crawford TL: Peritonitis in continuous cycler peritoneal dialysis. Adv Perit Dial 18:161-164, 2002
20. Yishak A, Bernardini J, Fried L, Piraino B: The outcome of peritonitis in patients on automated peritoneal dialysis. Adv Perit Dial 17:205-208, 2001
21. Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW, Strife F, Hamburger RJ: Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Am J Kidney Dis 28:428-136, 1996
22. Gupta B, Bernardini J, Piraino B: Peritonitis associated with exit site and tunnel infections. Am J Kidney Dis 28:415-419, 1996
23. Twardowski ZJ, Prowant BF: Classification of normal and diseased exit sites. Perit Dial Int 16(suppl 3):S32-S50, 1996
24. Gokal R, Alexander S, Ash S, Chen TW, Danielson A, Holmes C, Joffe P, Moncrief J, Nichols K, Piraino B, Prowant B, Slingeneyer A, Stegmayr B, Twardowski Z, Vas SI: Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. Perit Dial Int 18:11-33, 1998
25. Prowant BF, Schmidt LM, Twardowski ZJ, Griebel CK, Burrows LK, Ryan LP, Satalowich RJ: Peritoneal dialysis catheter exit site care. ANNA J 15:219-223, 1988
26. Keane FW, Everett DE, Fine RN, et al.: CAPD related peritonitis management and antibiotic therapy recommendations. Travenol Peritonitis Management Advisory Committee. Perit Dial Bull 7:55-62, 1987
27. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Huang CC, Kawaguchi Y, Piraino B, Riella M, Schaefer F, Vas S: Peritoneal dialysis-peritonitis treatment recommendations: 1996 update. Perit Dial Int 16:557-573, 1996
28. Troidle L, Kliger AS, Gorban-Brennan N, Fikrig M, Golden M, Finkelstein FO: Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 50:1368-1372, 1996
29. Carey HB, Troidle L, Kliger AS, Finkelstein FO: VRE peritonitis: a case report and review of the literature. Semin Dial 12:333-336, 1999
30. Hospital Infection Control Practices Advisory Committee (HICPAC): Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 16:105-113, 1995
31. Noble WC, Virani Z, Cree RGA: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 93:195-198, 1992
32. Chang S, Sievert D, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348:1342-1347, 2003
33. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR Morb Mortal Wkly Rep 48:1165-1167, 2000
34. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 51:565-567, 2002
35. Goldie SJ, Kiernan-Troidle L, Torres C, Gorban-Brennan N, Dunne D, Kliger AS, Finkelstein FO: Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Am J Kidney Dis 28:86-91, 1996
36. Eisenberg ES, Leviton I, Soeiro R: Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Rev Infect Dis 8:309-321, 1986
37. Lo WK, Chan CY, Cheng SW, Poon JFM, Chan DTM, Cheng IKP: A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 28:549-552, 1996
38. Sewell CM, Clarridge J, Lacke C, Weinman EJ, Young EJ: Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA 248:1493-1495, 1982
39. Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Carmona A, Adeva M, Rodriguez-Lozano I, Moncalian J: Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 22:708-712, 1993
40. Mupirocin Study Group: Nasal mupirocin prevents Staphylococcus aureus infection during peritoneal dialysis. J Am Soc Nephrol 7:2403-2408, 1996
41. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R: A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 27:695-700, 1996
42. Cookson BD: The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 41:11-18, 1998
43. Boyce JM: Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hosp Epidemiol 17:775-779, 1996
44. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Garcia Falcon T, Valdes F: Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39:337-341, 2002
45. Conly JM, Vas S: Increasing mupirocin resistance of Staphylococcus aureus in CAPD - should it continue to be used as prophylaxis? Perit Dial Int 22:649-652, 2002
46. Kimmel PL, Weihs KL, Peterson RA: Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 4:12-27, 1993
47. Juergensen PH, Juergensen DM, Wuerth DB, Finkelstein SH, Steele TE, Kliger AS, Finkelstein FO: Psychosocial factors and incidence of peritonitis. Adv Perit Dial 12:196-198, 1996
48. Troidle L, Watnick S, Wuerth DB, Gorban-Brennan N, Kliger AS, Finkelstein FO: Depression and its association with peritonitis in CPD patients. Am J Kidney Dis, 42:350-354, 2003
49. Wuerth DB, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO: Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis 37:1011-1017, 2001
50. Juergensen PH, Finkelstein F, Brennan R, Santacroce S, Ahern MJ: Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six-year study. Am J Kidney Dis 11:413-417, 1988
51. Szeto CC, Chow KM, Leung CB, Wong TYH, Wu AKL, Wang AYM, Lui SF, Li PKT: Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int 59:2309-2315, 2001
52. Troidle L, Gorban-Brennan N, Kliger AS, Finkelstein FO: Effect of duration of chronic peritoneal dialysis therapy on the development of peritonitis. Perit Dial Int 19:376-379, 1999
53. Bunke MC, Brier ME, Golper TA, Academic Subcommittee of the Network 9 Peritonitis Study: Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 peritonitis study. Kidney Int 52:524-529, 1997
54. Troidle L, Gorban-Brennan N, Finkelstein F: Peritonitis with Staphylococcus aureus. J Am Soc Nephrol 13:384, 2002
55. Troidle L, Gorban-Brennan N, Kliger AS, Finkelstein FO: Staphylococcus peritonitis: What do we really understand? Perit Dial Int 20(suppl 1):S43, 2000
56. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322, 1999
57. Dasgupta MK, Ward K, Noble P, Larabie M, Costerton JW: Development of bacterial biofilms on silastic catheter materials in peritoneal dialysis fluid. Am J Kidney Dis 23:709-716, 1994
58. Khaled GH, Finkelstein FO, Carey HB, Wardlaw SC, Kliger AS, Edberg SC: Method for studying development of colonization and infection of dialysis catheters. Adv Perit Dial 17:163-171, 2001
59. Dasgupta MK: Biofilms and infection in dialysis patients. Semin Dial 15:338-346, 2002
60. Troidle L, Gorban-Brennan N, Khaled GH, Edberg SC, Finkelstein FO: Biofilm and its clinical significance. Perit Dial Int 22(suppl 1):2002
61. Boroujerdi-Rad H, Juergensen P, Mansourian V, Kliger AS, Finkelstein FO: Abdominal abscesses complicating peritonitis in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 23:717-721, 1994
62. Manley HJ, Bailie GR: Treatment of peritonitis in APD: pharmacokinetic principles. Semin Dial 15:418-421, 2002
63. Elwell RJ, Bailie GR, Manley HJ: Correlation of intraperitoneal antibiotic pharmacokinetics and peritoneal membrane transport characteristics. Perit Dial Int 20:694-698, 2000
64. Low CL, Gopalakrishna K, Lye WC: Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 11:1117-1121, 2000
65. Wong KM, Chan YH, Cheung CY, Chak WL, Choi KS, Leung SH, Leung J, Chau KF, Tsang DN, Li CS: Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 38:127-131, 2001
66. Lye WC, van der Straaten JC, Leong SO, Silvarman P, Tan CC, Lee EJ: Once-daily intraperitoneal gentamicin is effective therapy for gram-negative CAPD patients. Perit Dial Int 19:357-360, 1999
67. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF: Pharmacokinetics of intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19:65-70, 1999
68. Vas SI: Single daily dose of aminoglycosides in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 13(suppl 2):S355-S356, 1993
69. Morse GD, Farolino DF, Apicella MA, Walshe JJ: Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 31:173-177, 1987
70. Tosukhowong T, Eiam-Ong S, Thamutok K, Wittayalertpanya S, Na Ayudhya DP: Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous peritoneal dialysis patients. Perit Dial Int 21:587-594, 2001
71. Manley HJ, Bailie GR, Frye RF, McGoldrick MD: Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 21:378-385, 2001
72. Manley HJ, Bailie GR, Frye R, Hess LD, McGoldrick MD: Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. J Am Soc Nephrol 11:1310-1316, 2000
73. Manley HJ, Bailie GR, Frye R, McGoldrick MD: Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis. Perit Dial Int 20:686-693, 2000
74. Elwell RJ, Frye RF, Ganchuk SR, Bailie GR: Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis. Perit Dial Int 23(suppl 1):S37, 2003
75. Elwell RJ, Manley HJ, Bailie GR: Comparison of intraperitoneal ceftazidime pharmacokinetics in CAPD and APD patients. J Am Soc Nephrol 13:383A, 2002
76. Finelli A, Gallant CV, Jarvi K, Burrows LL: Use of in-biofilm expression technology to identify genes involved in Pseudomonas aeruginosa development. J Bacteriol 185:2700-2710, 2003
77. Stewart PS, Costerton JW: Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138, 2001
78. Drenkard E, Ausubel FM: Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740-743, 2002
79. Sepandj F, Ceri H, Gibb AP, Read RR, Olson M: Biofilm infections in peritoneal dialysis-related peritonitis: comparison of standard MIC and MBEC in evaluation of antibiotic sensitivity of coagulase-negative staphylococci. Perit Dial Int 23:77-79, 2003
80. Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE: C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 360:1462-1467, 2002
81. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565, 2002
82. Paniagua R, Frias Y, Ventura MDJ, Rodriguez E, Hurtado ME, Alcantara G, Vazquez R, Ortiz R, Salcedo M, Rios ME, Kaji J, Amato D: C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis. Perit Dial Int 23:132-137, 2003
83. Kim SB, Min WK, Lee SK, Park JS, Hong CD, Yang WS: Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 39:342-346, 2002
84. Wanner C, Zimmermann J, Schweldler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int 61(suppl 80):S99-S102, 2002
85. Syrjala H, Linnanvuo-Laitinen M, Huttunen K: Peritoneal effluent leukocytes and serum C-reactive protein during peritoneal dialysis-associated peritonitis. Perit Dial Int 10:109-110, 1990
86. Hind CR, Thomson SP, Winearls CG, Pepys MB: Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis. J Clin Pathol 38:459-463, 1985
87. Troidle L, Mahajan A, Gorban-Brennan N, Kliger AS, Finkelstein F: C-reactive protein, peritonitis and outcome. Perit Dial Int 21(suppl 1):S45, 2001
88. Gorban-Brennan N, Troidle L, Kliger AS, Finkelstein FO: Peritonitis and its relationship with death in a large CPD cohort. Perit Dial Int 19(suppl 1):S31, 1999
89. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, Jones ME: The prevalence of low-and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 42:489-495, 1998
90. Yun HJ, Lee SW, Yoon GM, Kim SY, Choi S, Lee YS, Choi EC, Kim S: Prevalence and mechanisms of low-and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 51:619-623, 2003
91. Miller MA, Dascal A, Portnoy J, Mendelson J: Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus (MRSA) after widespread use of nasal mupirocin ointment. Infect Control Hasp Epidemiol 17:811-813, 1996
92. Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, Jassal V, Oreopoulos D: Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 21:554-559, 2001
93. Berns JS, Tokars JI: Preventing bacterial infections and antimicrobial resistance in dialysis patients. Am J Kidney Dis 40:886-898, 2002
94. Maki DG, Mermel LA, Kluger D, Narans L, Knasinski V, Parenteau S, Covington P: The efficacy of a chlorhexidine-impregnated sponge (Biopatch) for the prevention of intravascular catheter-related infection - a prospective, randomized, controlled, multicenter study [abstract]. American Society for Microbiology Meeting, 40th ICAAC, September 2000
95. Stickler DJ: Susceptibility of antibiotic-resistant gram-negative bacteria to biocides: a perspective from the study of catheter biofilms. Appl Microbiol 31:S163-S170, 2002
96. Quickel KE, Selden R, Caldwell JR, Nora NF, Schaffner W: Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl Microbial 22:446-450, 1971
97. Walsh S, Shah A, Mond J: Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 47:554-558, 2003
98. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ: Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47:1589-1597, 2003
99. Patron RL, Climo MW, Goldstein BP, Archer GL: Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 43:1754-1755, 1999
100. Jones T: StaphVAX (Nabi). Curr Opin Invest Drugs 3:48-50, 2002
101. Pelton SI: Acute otitis media in the era of effective pneumococcal conjugate vaccine: Will new pathogens emerge? Vaccine 19(suppl 1):S96-S99, 2000
102. Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Sollner J, Schmidt W, von Ahsen U, Buschle M, Gill SR, Kolonay J, Khalak H, Fraser CM, von Gabain A, Meinke A: Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99:6573-6578, 2002
103. Balaban N, Gov Y, Bitler A, Boelaert JR: Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells. Kidney Int 63:340-345, 2003
104. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP: The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280:295-298, 1998
105. Balaban N, Giacometti A, Cirioni O, Gov Y, Ghiselli R, Mocchegiani F, Viticchi C, Simona Del Prete M, Saba V, Scalise G, Dell'Acqua G: Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis 187:625-630, 2003
106. Brooun A, Liu S, Lewis K: A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 44:640-646, 2000
107. Szeto CC, Chow KM, Wong TYH, Leung CB, Wang AYM, Lui SF, Li PKT: Feasibility of resuming peritoneal dialysis after severe peritonitis and Tenckhoff catheter removal. J Am Soc Nephrol 13:1040-1045, 2002
108. Troidle L, Gorban-Brennan N, Carey H, Finkelstein FO: Peritoneal catheter reinsertion after peritonitis. Perit Dial Int 23(suppl 1):S41, 2003